摘要
目的分析急性脑梗死后血清甲状腺激素水平与认知功能的相关性。方法选取2019年1月—2020年12月收治的急性脑梗死200例作为研究对象,依据蒙特利尔认知评估(MoCA)量表评分分为A组(认知功能正常)85例和B组(认知功能障碍)115例。比较2组一般临床资料及血清甲状腺相关激素水平,分析急性脑梗死后认知功能障碍的危险因素。结果急性脑梗死2周时认知功能障碍发生率为57.50%。与A组比较,B组脑梗死病史比例增高(P<0.05)。与A组比较,B组血清游离三碘甲状腺原氨酸(FT_(3))水平降低,促甲状腺激素(TSH)水平升高(P<0.05)。TSH是急性脑梗死后认知功能障碍的独立危险因素,而FT_(3)则是保护因素。结论急性脑梗死后认知功能障碍发生率较高,血清TSH是其独立危险因素,而FT_(3)是保护因素。
Objective To analyze the correlation between serum level of thyroid hormone with cognitive function in patients after acute cerebral infarction(ACI).Methods A total of 200 patients with ACI admitted between January 2019 and December 2020 were selected as research subjects,and the patients were divided into group A(having normal cognitive function,n=85)and group B(having cognitive impairment,n=115)according to Montreal Cognitive Assessment(MoCA)scores.General clinical data and serum level of thyroid hormone were compared between two groups,and the independent risk factors of cognitive impairment in patients after ACI were analyzed.Results Incidence rate of cognitive dysfunction in patients after ACI for 2 weeks was 57.50%.The proportion of cerebral infarction history in group B was higher than that in group A(P<0.05).Compared with those in group A,serum level of free triiodothyronine(FT_(3))was significantly decreased,while the level of thyroid-stimulating hormone(TSH)was significantly increased in group B(P<0.05).TSH was an independent risk factor of cognitive dysfunction,and FT_(3)was a protective factor in patients after ACI.Conclusion The incidence rate of cognitive dysfunction is high in patients after ACI,and serum TSH is an independent risk factor,while FT_(3)is a protective factor.
作者
孔伟丽
王琴
吕康
徐爱兰
刘慧
王永会
刘兰丽
KONG Wei-li;WANG Qin;LYU Kang;XU Ai-lan;LIU Hui;WANG Yong-hui;LIU Lan-li(Department of Neurology,People's Hospital of Dingzhou City,Dingzhou,Hebei 073000,China;Department of Critical Medicine,People's Hospital of Dingzhou City,Dingzhou,Hebei 073000,China;Department of Clinical Laboratory,People's Hospital of Dingzhou City,Dingzhou,Hebei 073000,China)
出处
《解放军医药杂志》
CAS
2021年第10期77-79,83,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
河北省医学科学研究重点课题计划项目(20191745)。
